TP53 and lung cancer: In contrast, You et al. (2000) found that the synergistic effect of ONYX-015 and paclitaxel and cisplatin in lung cancer cells was p53 mutant dependent, and Rogulski et al. (2000) and colleagues showed that additive effects of radiation and ONYX-015 in human colon carcinoma were limited to ONYX-015-sensitive, p53-deficient tumours.